Lung Cancer Stages: What Each Stage Means for Treatment and Prognosis

Key Takeaways

• Staging uses the TNM system: Tumor size and extent (T), lymph node involvement (N), and distant metastasis (M) combine to determine your cancer stage, which ranges from 0 to IV.

• NSCLC and SCLC are staged differently: Non-small cell lung cancer (NSCLC) uses the detailed TNM system, while small cell lung cancer (SCLC) uses the simpler limited-stage versus extensive-stage classification because of its different behavior.

• Stage guides treatment decisions: Early-stage cancers are often treated with surgery, locally advanced disease typically requires chemotherapy and/or radiation, and advanced disease calls for systemic therapies tailored to biomarkers.

• Staging relies on multiple tests: CT, PET, and brain MRI scans, plus lymph node sampling and tissue biopsy, provide the information needed for accurate staging.

• Statistics inform but don't predict individual outcomes: 5-year survival rates vary dramatically by stage, but your personal prognosis depends on factors including your health, specific mutations, age, and treatment response.

• Clinical trials are available at every stage: Many trials target specific stages and may offer access to newer treatments that could improve outcomes beyond standard care alone.

Introduction

When you're diagnosed with lung cancer, one of the first things your oncologist will do is determine your cancer's stage. Staging tells you and your care team how much cancer is present, where it's located, and whether it has spread — information that directly shapes your treatment plan and prognosis. According to the American Lung Association, lung cancer staging uses a standardized system that helps doctors communicate clearly about disease extent and guides decisions about surgery, chemotherapy, radiation, and other therapies.

Many patients wonder what their stage number really means and whether it predicts their individual outcome. The truth is more nuanced: while staging is invaluable for treatment planning and comparing research results, your personal prognosis depends on many factors beyond stage, including your age, overall health, specific mutations in your cancer cells, and how your body responds to treatment. Understanding the basics of lung cancer staging, how it works, what each stage means, and how it influences your care empowers you to ask better questions, weigh your options thoughtfully, and participate more fully in decisions about your health.

This guide walks you through the staging systems used for lung cancer, explains what each stage involves, and shows how staging affects treatment and prognosis. Whether you've recently been diagnosed or are supporting a loved one, this information can help you navigate your care journey with confidence.

How Lung Cancer Is Staged

Lung cancer staging relies primarily on the TNM system, a standardized classification adopted by major medical organizations including the American Joint Committee on Cancer (AJCC). The AJCC 8th edition staging system, updated in 2017, is the current standard used worldwide.

Understanding the TNM System

The TNM system breaks down into three key components:

T (Tumor): This describes the size and extent of the primary tumor in your lungs. Doctors measure how large the tumor is and whether it has invaded nearby structures like the chest wall, diaphragm, or airway. T categories range from T0 (no tumor) to T4 (large tumor with extensive local invasion).

N (Node): This refers to whether cancer has spread to nearby lymph nodes in the chest. Lymph nodes are small glands that filter immune cells and can trap cancer cells. The N category indicates the presence and location of involved lymph nodes: N0 means no lymph node involvement, while N1, N2, and N3 indicate increasing involvement of regional lymph nodes.

M (Metastasis): This describes whether cancer has spread (metastasized) to distant sites like the brain, bones, liver, or the other lung. M0 means no distant metastases, while M1 indicates distant spread (with M1a and M1b designations based on the specific location of metastases).

By combining these three components — for example, a T3 N1 M0 tumor — doctors create a detailed picture of your cancer's extent.

From TNM to Stage Groupings

The TNM values are then combined into overall stages that range from 0 to IV (0, I, II, III, and IV). This grouping system allows doctors to discuss prognosis and treatment more efficiently. For example, a very small tumor with no lymph node involvement and no distant metastases might be grouped as Stage I, while a larger tumor with lymph node involvement but still confined to the chest might be Stage III.

The specific TNM combinations that define each stage differ between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) because these two types of lung cancer have different patterns of growth and spread.

Imaging and Procedures Used for Staging

To accurately stage your lung cancer, your oncologist will order several tests:

• CT (computed tomography) scans of the chest, abdomen, and pelvis reveal the size and location of the primary tumor, involvement of lymph nodes, and the presence of tumors in other organs.

• Positron emission tomography (PET) scans use a radioactive tracer to identify areas of abnormal activity, helping detect metastases that might not be visible on CT alone.

• Brain MRI screens for metastases to the brain, which are common in advanced lung cancer.

• Bone scans or dedicated bone imaging may be performed if bone metastases are suspected.

• Endobronchial ultrasound (EBUS) and mediastinoscopy are minimally invasive procedures that allow your doctor to sample lymph nodes directly, confirming whether they contain cancer cells.

A biopsy — collection of tissue samples for microscopic examination — is also essential. This identifies your cancer's specific type (NSCLC vs. SCLC), histology (adenocarcinoma, squamous cell, etc.), and biomarkers like PD-L1 expression, and other mutations and rearrangements like EGFR, RAS, and ALK. Biomarkers often influence treatment decisions and eligibility for targeted therapies or immunotherapy trials.

Non-Small Cell Lung Cancer (NSCLC) Stages

NSCLC accounts for approximately 85% of all lung cancers. It tends to grow more slowly than small cell lung cancer and responds well to surgery when caught early.

Stage 0: Carcinoma In Situ

Stage 0 (carcinoma in situ) represents abnormal cells in the lung lining that have not yet invaded deeper tissues. It's an extremely early form and, according to the American Cancer Society, is sometimes considered pre-cancer. At this stage, the cancer is usually confined to the airways and hasn't formed a measurable tumor. Treatment typically involves observation or removal of the affected airway tissue through endoscopic procedures, avoiding the need for major surgery in many cases.

Stage I: Early-Stage Disease

Stage I is divided into substages IA and IB, which differ based on tumor size and extent.

Stage IA is further subdivided into IA1, IA2, and IA3 based on tumor size:

• IA1: Tumors measuring 1 cm or smaller, with no lymph node involvement or distant metastases.

• IA2: Tumors larger than 1 cm but no more than 2 cm.

• IA3: Tumors larger than 2 cm but no more than 3 cm.

Stage IB: Tumors larger than 3 cm but not exceeding 4 cm, or tumors of any size that have spread to the innermost membrane surrounding the lung.

At Stage I, cancer is localized to the lung without metastatic spread. Surgery is typically the primary treatment, with the goal of complete removal of the tumor and a margin of healthy tissue. Many Stage I patients have excellent prognosis, particularly those with the smallest tumors.

Stage II: Locally Advanced with Some Spread

Stage II lung cancer includes tumors that are larger than Stage I or show early spread to nearby lymph nodes.

Stage IIA includes tumors up to 5 cm with spread to nearby lymph nodes on the same side of the chest (N1), or tumors larger than 4 cm without lymph node involvement.

Stage IIB encompasses tumors up to 7 cm with N1 involvement, or larger tumors without nodal involvement.

At Stage II, surgery remains a central treatment option, often combined with adjuvant (post-surgery) chemotherapy to eliminate any remaining cancer cells. Adjuvant chemotherapy has been shown to improve survival in certain Stage II patients, particularly those with larger tumors or more extensive lymph node involvement.

Stage III: Locally Advanced with Significant Lymph Node Involvement

Stage III is a heterogeneous category with substantial variation in tumor extent and lymph node involvement. It's divided into IIIA, IIIB, and IIIC.

Stage IIIA typically involves tumors of various sizes with spread to lymph nodes on the same side of the chest (N1 or N2). The cancer remains confined to the ipsilateral (same-side) hemithorax.

Stage IIIB includes larger tumors and/or involvement of lymph nodes in the midline or on the opposite side of the chest (N3).

Stage IIIC represents the most advanced locally advanced disease, with extensive lymph node involvement and/or invasion of vital structures like the heart or esophagus.

Stage III is considered "locally advanced" because it has not spread to distant organs, but it has spread significantly within the chest. Treatment is more complex and often combines multiple modalities: neoadjuvant chemotherapy followed by surgery, concurrent chemotherapy and radiation therapy, or radiation therapy alone if surgery is not feasible. Some Stage III patients may also benefit from newer approaches such as immunotherapy combined with chemotherapy. Many clinical trials for locally advanced NSCLC are available and may offer options beyond standard treatment.

Stage IV: Metastatic Disease

Stage IV, also called metastatic or advanced lung cancer, indicates that cancer has spread to distant organs or to multiple areas of the lungs. It's divided into IVA and IVB based on the extent of spread.

Stage IVA: Cancer has spread to one distant site (such as the brain, bones, or liver) or to a small number of sites within the opposite lung.

Stage IVB: Widespread metastatic disease, with involvement of multiple distant organs or extensive involvement of the opposite lung.

Stage IV NSCLC is not curable with surgery or radiation alone. However, treatment has evolved dramatically over the past decade. Depending on your cancer's specific biomarkers — including mutations in EGFR, ALK, ROS1, BRAF, or expression of PD-L1 — your doctor may recommend targeted therapy, immunotherapy, chemotherapy, or combination approaches. Many patients with metastatic lung cancer now live months to years with treatment, and clinical trials continue to expand the arsenal of effective options.

Small Cell Lung Cancer (SCLC) Staging

SCLC represents approximately 15% of all lung cancers. It grows rapidly and tends to spread early, so it's treated differently from NSCLC.

The Limited-Stage vs. Extensive-Stage System

Unlike NSCLC, which uses the TNM system, SCLC traditionally uses a simpler two-stage classification:

Limited Stage (LS): Cancer is confined to the lungs and regional lymph nodes on one side of the chest and can be encompassed within a single radiation field. Limited-stage SCLC is potentially curable, and treatment typically involves concurrent chemotherapy and radiation therapy.

Extensive Stage (ES): Cancer has spread beyond one side of the chest, involving the opposite lung, lymph nodes on the opposite side, distant organs, or the fluid around the lungs. Extensive-stage SCLC is incurable with current treatments, but chemotherapy and newer immunotherapy approaches can significantly extend survival and improve quality of life.

SCLC and the TNM System

While the limited/extensive staging system remains standard for SCLC, the AJCC also provides TNM staging for SCLC to allow comparison with NSCLC and for research purposes. In TNM terms, limited-stage SCLC corresponds roughly to Stage I through III, while extensive-stage SCLC aligns with Stage IV. However, because SCLC's behavior is so distinct, the simpler limited/extensive classification remains the most practical guide for treatment decisions.

Treatment Options by Stage

Your cancer stage is one of several factors that guide treatment decisions. Your overall health, age, lung function, biomarkers, and personal preferences also play important roles.

Early-Stage Disease (Stage 0–IB)

Early-stage NSCLC is often treated with surgery, with the goal of removing the tumor and surrounding tissue while preserving as much healthy lung as possible. Surgical options include lobectomy (removal of one lobe) or segmentectomy (removal of a smaller portion). In some cases, particularly for very small tumors in patients who are not candidates for major surgery, stereotactic body radiation therapy (SBRT) — a form of precise, high-dose radiation delivered in few sessions — offers an alternative.

Adjuvant therapy (treatment given after surgery) may be recommended if your tumor is larger than 1 cm or if lymph nodes were involved, to reduce the risk of recurrence.

Locally Advanced Disease (Stage II–IIIC)

Stage II and III NSCLC often require multimodal treatment combining two or more approaches. Common strategies include:

• Neoadjuvant chemotherapy chemotherapy followed by surgery (downstaging the tumor to improve surgical outcomes)

• Concurrent chemotherapy and radiation therapy (using both treatments simultaneously to maximize benefit)

• Radiation alone if surgery is not feasible

Recent advances include the addition of immunotherapy to these approaches, which has improved outcomes for some Stage III patients.

For limited-stage SCLC, concurrent chemotherapy and radiation is the standard, typically followed by prophylactic cranial irradiation (PCI) to reduce brain metastases.

Advanced Disease (Stage IV)

Stage IV NSCLC treatment depends heavily on biomarkers. Patients with EGFR mutations, ALK or ROS1 rearrangements, or other actionable mutations may benefit from targeted therapy, which often has fewer side effects and better initial response rates than chemotherapy. Patients without these mutations or those whose mutations no longer respond to targeted therapy may receive chemotherapy alone or combined chemotherapy and immunotherapy.

Immunotherapy has become a cornerstone of advanced NSCLC treatment, particularly for patients with high PD-L1 expression. Some trials now combine immunotherapy with targeted therapy for patients with specific mutations, offering personalized options.

For extensive-stage SCLC, chemotherapy (typically platinum-based) is the standard first treatment. Immunotherapy is increasingly added, and many trials explore new combinations.

For detailed information on all treatment options, visit our guide to lung cancer treatment.

Prognosis and Survival by Stage

Understanding your prognosis — the likely course of your disease — requires both realistic information about statistics and recognition that every patient is unique.

The SEER database, maintained by the National Cancer Institute, groups lung cancer survival data by how far the cancer has spread rather than by individual TNM stage. According to the American Cancer Society, based on diagnoses between 2015 and 2021, 5-year survival rates for NSCLC are:

•   Localized (cancer confined to the lung): approximately 67%

•   Regional (cancer spread to nearby lymph nodes or structures): approximately 40%

•   Distant (cancer spread to other organs): approximately 12%

For SCLC, 5-year survival rates are considerably lower:

•   Localized: approximately 34%

•   Regional: approximately 20%

•   Distant: approximately 4%

Keep in mind that these statistics reflect diagnoses and treatments from several years ago. People diagnosed today may have a better outlook as treatments, particularly immunotherapy and targeted therapy, have advanced significantly in recent years.

Important Context for These Statistics

These figures are population averages from thousands of patients and represent outcomes from several years ago. Several crucial points deserve emphasis:

These are not individual predictions. Your personal prognosis may differ significantly based on your unique circumstances, cancer characteristics, and treatment response.

Outcomes continue to improve. The data reflect average results; newer treatments, particularly targeted therapies and immunotherapies, have improved outcomes for many patients since these statistics were gathered. Clinical trials often offer access to even newer approaches.

Factors beyond stage matter. Age, overall health, smoking history, specific genetic mutations in your tumor, and how your body responds to treatment all influence your actual prognosis.

Long-term survival is increasingly common. Many patients diagnosed even with advanced lung cancer now live well beyond the initial statistics, especially those with actionable mutations or whose cancers respond well to newer therapies.

For more detailed prognostic information tailored to specific characteristics, visit our lung cancer survival rates guide.

How Staging Connects to Clinical Trials

Your cancer stage is often a key eligibility criterion for clinical trials. Many trials target specific stages because different stages have different treatment needs and require different types of evidence.

• Early-stage trials may test new approaches to surgery, adjuvant chemotherapy, or radiation therapy, with the goal of improving cure rates.

• Locally advanced trials often explore combinations of chemotherapy, radiation, and immunotherapy to improve outcomes when surgery isn't feasible.

• Advanced-stage trials investigate new systemic therapies — targeted drugs, immunotherapies, or combinations — designed to extend survival and improve quality of life.

Importantly, clinical trials exist at every stage of lung cancer. Many early-stage patients benefit from trials testing adjuvant therapies or novel surgical approaches. Patients with advanced disease have access to trials exploring the newest targeted therapies, immunotherapy combinations, and personalized medicine approaches.

Understanding your stage helps you and your doctor identify trials that match your disease extent and treatment goals. Some trials may offer access to cutting-edge drugs not yet widely available, potentially improving your outcomes beyond standard treatment alone.

Frequently Asked Questions

What is the difference between cancer staging and grading?

Staging describes the extent and spread of your cancer, using the TNM system to determine how much cancer is present and where. Grading, by contrast, refers to how abnormal the cancer cells appear under a microscope and how quickly they're likely to grow. Both are important for treatment planning, but they measure different things. Your doctor will provide both your stage and your grade to give a complete picture of your disease.

Can staging change after I start treatment?

In some cases, yes. If you receive neoadjuvant therapy (treatment before surgery), the cancer may shrink, and your stage could change when re-staged after treatment. However, your initial stage remains important for determining your initial treatment approach. Always ask your doctor whether restaging is planned and what it might mean for your treatment plan.

Is Stage IV lung cancer always fatal?

No. While Stage IV (metastatic) lung cancer is not curable with current treatments, many patients live for years and continue to enjoy quality of life. Newer targeted therapy and immunotherapy have dramatically improved outcomes for advanced lung cancer. The disease is now often managed more like a chronic condition than an immediately fatal diagnosis, and ongoing research continues to expand treatment options. Clinical trials may offer additional approaches that could further extend survival.

How often is staging reassessed?

Staging is typically determined at diagnosis to guide initial treatment. Restaging may occur before or after major treatments like surgery or chemotherapy to assess response. During ongoing treatment, imaging may be performed periodically to monitor for progression or recurrence, but formal TNM restaging is less common unless treatment decisions need to be reassessed. Ask your oncologist about their specific restaging plan for your situation.

What should I ask my oncologist about my stage?

Excellent questions include: "What do all the TNM numbers and letters in my stage mean?"; "Does my cancer have any biomarkers that would make me eligible for targeted therapy or immunotherapy?"; "What are the goals of my recommended treatment plan?"; "Are there clinical trials that might be appropriate for me at my stage?"; and "How will we know if treatment is working, and when will we reassess?" These questions help ensure you fully understand your diagnosis and participate meaningfully in treatment decisions.

Ready to explore clinical trials that may be right for you? Start your search with North's trial finder.

References

1. American Cancer Society. "Lung Cancer Key Statistics." cancer.org.

2. Goldstraw, P., Chansky, K., Crowley, J., et al. "The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer." Journal of Thoracic Oncology. 2016;11(1):39–51.

3. National Cancer Institute. "Lung Cancer — Patient Version." cancer.gov.

4. National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer." nccn.org.

5. Strand, T. E., Rostad, H., Møller, B., & Norstein, J. "Survival after Resection for Primary Lung Cancer: A Population Based Study of 3,211 Resected Patients." Thorax. 2006;61(8):710–715.

6. Zappa, C., & Mousa, S. A. "Non-Small Cell Lung Cancer: Current Treatment and Future Advances." Translational Lung Cancer Research. 2016;5(3):288–300.